Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Total 13F shares
-
29,681,761
-
Share change
-
+2,898,516
-
Total reported value
-
$157,343,204
-
Put/Call ratio
-
3.8%
-
Price per share
-
$5.30
-
Number of holders
-
95
-
Value change
-
+$15,794,537
-
Number of buys
-
54
-
Number of sells
-
34
Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2024
As of 31 Mar 2024,
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,681,761 shares.
The largest 10 holders included
VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Frazier Life Sciences Management, L.P., ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Camber Capital Management LP, BlackRock Inc., Eversept Partners, LP, GREAT POINT PARTNERS LLC, and Athyrium Capital Management, LP.
This page lists
92
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.